Integrative Approaches for Cancer Survivorship 3

Inclusion Criteria

• Age ≥ 18
• Able to understand study procedures and to comply with them for the entire length of the study
• Able to read, write, and understand English
• Ability of individual or legal guardian/representative to understand an informed consent document, and the willingness to sign it
• Non-metastatic breast cancer patients who are between 1 and 36 months after completion of primary treatment (i.e., surgery, radiotherapy, chemotherapy) and are in a complete remission
• Patients should have received chemotherapy as part of their primary treatment
• Have an impaired quality of life (report a score of 5 or less on question 30 of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQ C30]. “How would you rate your overall quality of life during the past week?” [Answers range from 1 – very poor to 7 – excellent])
• Performance status score (Karnofsky performance status [KPS]) ≥ 60

Exclusion Criteria

• Contraindication to any study-related procedure or assessment
• Metastatic disease and receiving chemotherapy or radiotherapy at the time of study enrollment (patients with non-metastatic disease who are receiving anti-Her2 directed treatment alone in the adjuvant setting are eligible)
• Patients are within 1 month after surgery for cancer, including breast reconstructive surgery but not including implant exchange
• Cancer surgery planned during the initial 6-month study period
• Been on adjuvant hormone therapy (for breast cancer) less than 2 months at the time of enrollment
• Received Ayurvedic treatment during the 3 months preceding enrollment
• If a participant reports severe anxiety or depression, has severe depression assessed by Patient Health Questionnaire (PHQ)-9 using a cutoff of 20 or higher, or severe anxiety assessed by the General Anxiety Disorder (GAD)-7 using a cut off 15 or higher
• Current suicidal ideation (PHQ9 item 9 > 0 and Columbia-Suicide Severity Rating Scale [C-SSRS] response > low risk)